The global market for mRNA therapeutics should grow from $46.7 billion in 2021 to $101.3 billion by 2026, at a compound annual growth rate (CAGR) of 16.8% for the period of 2021-2026.
The U.S. market for mRNA therapeutics should grow from $21.5 billion in 2021 to $46.5 billion by 2026, at a CAGR of 16.7% for the period of 2021-2026.
The Asia-Pacific market for mRNA therapeutics should grow from $6.1 billion in 2021 to $13.8 billion by 2026, at a CAGR of 17.9% for the period of 2021-2026.
Report Scope
This report is an analytical business tool with the primary purpose of providing a thorough evaluation of the global market for mRNA therapeutics for the prevention of infectious diseases (through prophylactic vaccines) and treatment of chronic (e.g., cancer, heart diseases) and several other rare diseases.
The report considers only “Western” or modern drugs and excludes any other type of drugs such as alternative therapies. This report covers technologies used for the development and delivery of mRNA therapeutics.
This study aims to analyze the dynamics and forecasts of the mRNA therapeutics market worldwide and provides key market propositions over a five-year forecast period.
The report covers developed and emerging markets, and it provides:
- Detailed description, including demographics and cost burden, of various diseases including types of cancer (e.g., breast cancer and others), cardiovascular diseases (MI, IHD, etc.), infectious diseases (COVID-19, Zika, influenza, rabies, etc.), respiratory disorders, diabetes and rare disorders such as cystic fibrosis, OTC disorder, propionic acidemia, TTR amyloidosis and melanoma, among others.
- Detailed description and analysis of current mRNA therapeutics (mRNA vaccines, drugs and therapies).
- Market characterization, unmet need, and market size and segmentation (by region, segment, diseases).
- The current state of the market and the key markets for its future development.
- Major regional trends.
- Market drivers and restraints.
- Detailed market projections through 2026.
- Global competitive thrust in terms of competition and market shares.
- Key marketed and pipeline (research and development) products along with information about their regulatory status.
- Strategic landscape (mergers and acquisitions).
- Regulatory structure: new regulations that will influence the development of the mRNA therapeutics market.
- Pricing and reimbursement.
- Observations and conclusions on the future of mRNA therapeutics.
- Profiles of market participants and associations.
Report Includes:
- 32 data tables and 32 additional tables
- An overview of the global market for mRNA therapeutics
- Analyses of global market trends with data from 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
- Highlights of the major developments, pandemic threats, therapeutic developments, and technological developments of the mRNA therapeutics market
- Discussion on significant advantages of mRNA over protein or DNA-based delivery systems and description of demographic and economic trends, and outlook of the mRNA therapeutics market
- Evaluation of current market size and forecast and information on prophylactic vaccines, vaccine discovery and development, and R&D activities
- Analysis of the various innovative therapeutics as well as new promising vaccines intended for the prevention and treatment of various chronic and infectious diseases
- Assessment of regulatory structure, pricing and reimbursement scenario, and pipeline analysis of the new molecules & therapeutics
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
- Comprehensive company profiles of major players of the industry, including Amgen Inc., Eli Lilly and Co., GlaxoSmithKline Plc, Johnson & Johnson and Novartis
What is the estimated value of the Global mRNA Therapeutics Market?
What is the growth rate of the Global mRNA Therapeutics Market?
What is the forecasted size of the Global mRNA Therapeutics Market?
Who are the key companies in the Global mRNA Therapeutics Market?
| Report Attribute | Details |
|---|---|
| No. of Pages | 271 |
| Published | September 2021 |
| Forecast Period | 2021 - 2026 |
| Estimated Market Value ( USD | $ 46.7 Billion |
| Forecasted Market Value ( USD | $ 101.3 Billion |
| Compound Annual Growth Rate | 16.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 51 |
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Intended Audience
- Methodology and Information Sources
- Geographic Breakdown
- Analyst's Credentials
- Custom Research
- Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Target Diseases and Disorders
- Overview of Common Diseases and Disorders for mRNA Therapeutics
- Cancer
- Infectious Diseases
- Cardiovascular Disease
- Lifestyle Disorders
- Respiratory Disorders
- Musculoskeletal Disorders
- Gastrointestinal Disorders
- Urology Disorders
- Nephrology Disorders
- Immune Disorders
- Neurological Disorders
- Rare Diseases
- Other Disorders
- Tobacco Smoking and Associated Diseases
- Infectious Diseases: COVID-19 Pandemic Set the Stage for mRNA Therapeutics
- Chronic Diseases: Expanding Horizon for mRNA Therapeutics
- Rare Diseases: Large Unmet Need is Fueling mRNA Therapeutics
- Ageing, Gender and Onset of Diseases
- Global Demographics
- U.S. Demographics
- European Demographics
- Japanese Demographics
- Current Challenges and Future Directions
Chapter 4 RNA Therapeutics
- RNA Therapeutics Overview
- Evolution of RNA Therapeutics
- History of RNA Therapeutics
- Development of RNA Therapeutics and Types
- DNA vs. RNA Therapeutics
- Clinical Need for RNA Therapeutics
- Increasing Disease Population and Economic Burden
- Limitations of Traditional Therapeutics
- Therapeutic Limitations of Biologics
- Poor Management of Chronic Diseases
- Limited Treatment for Rare Diseases
- RNA Therapeutics
- Antisense Oligonucleotide (ASO) as Therapeutics
- Small Interfering RNA (siRNA) as Therapeutics
- miRNA as Therapeutics
- Aptamers as Therapeutics
- mRNA as Therapeutics
- Manufacturing RNA-Based Biopharmaceuticals
- Chromatographic Purification Steps
- Delivery of RNA Therapeutics
- Polymer Conjugation/Chemical Modification
- Encapsulation
- Lipid-Based Nanoparticles
- Polymer Nanomaterials
- Silica Nanoparticles
- Carbon and Gold Nanomaterials
- GalNAc
- Institution and Hospital-Based RNA Therapeutics
- Regulatory Influence on the Market for RNA Therapeutics
- Market Situation for RNA Therapeutics
- Well-Developed Markets
- Developing Markets
- Underdeveloped Markets
- Therapeutics and Cost Burden
- Unmet Need
- Current Challenges and Future Developments
Chapter 5 mRNA Vaccines
- Vaccines: Overview
- Vaccine-Based Disease Prevention
- Evolution of mRNA as Vaccine
- Clinical Need for mRNA Vaccines
- mRNA Vaccines and Types by Application
- Prophylactic/Protective Vaccines
- Therapeutic Vaccines
- mRNA Vaccine Product Segments
- Non-amplifying mRNA Vaccines
- Self-amplifying mRNA Vaccines
- Immunogenicity and mRNA Vaccines
- Optimizing Injection Routes
- Co-encapsulation of Other Stimulatory Molecules
- Formulation and Delivery of mRNA Vaccine
- Approaches for Enhancing mRNA Stability
- Advantages of mRNA Vaccines
- Traditional Vaccine vs. mRNA Vaccines
- Marketed/Commercial mRNA Vaccines
- Moderna
- BioNTech
- mRNA Vaccine Pipeline and New Developments
- mRNA Vaccine Pipeline by Company
- mRNA Vaccines: New Developments
- mRNA Vaccines and Future Pandemics
- Unmet Need
- Current Challenges and Future Outlook
Chapter 6 mRNA Drugs and Therapies
- Overview of Drugs and Therapeutics
- Therapeutic-Based Disease Treatment
- Evolution of mRNA: Beyond Vaccines
- Clinical Need for mRNA Therapeutics Beyond Vaccines
- mRNA Vaccines vs. mRNA Therapeutics
- mRNA Therapeutics and Types
- mRNA as Gene and Protein Replacement Therapy
- mRNA-Enhanced Cell Therapies
- mRNA-Enhanced Immunotherapies (Monoclonal Antibody)
- Advantages mRNA Drugs and Therapies
- Delivery of mRNA Therapeutics
- mRNA Therapeutics Pipeline and New Developments
- mRNA Drugs for Protein Therapy Targeting Metabolic and Rare Diseases
- Pipeline for mRNA-Therapeutics by Company
- Pipeline for mRNA-Enhanced Cell Therapies
- mRNA Therapeutics and New Developments
- Widespread Concerns over the mRNA Medicinal Industry
- Issues with Personalized Medicine
- Unmet Need for mRNA Therapeutics
- Current Challenges and Future Outlook
Chapter 7 Market Size and Growth Analysis
- Overview
- Market Size and Growth Analysis by Region
- Market Size and Growth Analysis by Product Segment
- mRNA Vaccines vs. Traditional Vaccines
- mRNA Drugs and Therapies
- Market Size and Growth Analysis by Therapeutic Treatment Type
- Market Size and Growth Analysis by Disease Type
- Market Growth Drivers and Restraints
- Market Growth Drivers
- Market Restraints
- Regulatory Impact on the Market for mRNA Therapeutics
- SWOT Analysis of the Market for mRNA Therapeutics
Chapter 8 Competitive Landscape in the Market for mRNA Therapeutics
- Disease Prevention and Treatment with mRNA Therapeutics
Chapter 9 Strategies in the Market for mRNA Therapeutics
- Consolidation in the Pharmaceutical Market
- Mergers and Acquisitions in the Biopharmaceutical Market
- Recent Strategic Moves in mRNA Therapeutics
- Key M&A and In-licensing Deals
- Key Strategic Partnerships
- Key Venture Financing Deals
- Future Strategic Landscape
Chapter 10 Regulatory Structure for Biopharmaceuticals
- Regulatory Background
- Regulatory Systems for Biopharmaceuticals by Region
- United States
- Europe
- Japan
- Regulatory Systems for Medical Devices by Region
- United States
- European Union
- Japan
- Regulations for mRNA Therapeutics
- Current Regulatory Issues for mRNA Therapeutics
- Moderna Vaccine Regulation in the U.K.
- Key Regulatory Updates, 2020
- Pharmaceuticals
- Medical Devices
Chapter 11 Pricing and Reimbursement: Pharmaceuticals and Biologics
- Pricing and Reimbursement Background
- Pricing and Reimbursement of Pharmaceuticals and Biologics by Region
- United States
- Private Health Insurance
- Chronic Diseases and Cost Burden on Medicare
- Rise of Infectious Diseases and Pricing & Reimbursement for Vaccines in the US.
- Europe
- Japan
- Pricing and Reimbursement Challenges for Pharmaceuticals
- Patented Medicines Price
- Prices of Older Drugs
- Pricing and Reimbursement for Medical Devices by Region
- United States
- Europe
- Japan
- Other Parts of Asia-Pacific
Chapter 12 Conclusions on the Outlook for mRNA Therapeutics
- Major Developments Influencing the Market
- Digital Transformation and Technological Developments
- Increasing R&D Spend and Shift Towards Modern Therapeutics and Technologies
- Collaborations for Advanced Therapeutics
- Market Consolidation for Strategic Growth and to Retain Market Leadership
- Demographic and Economic Trends
- Changing Structure of the Pharma and Healthcare Industry
- Lifestyle Medicine
- Patient-Centric Programs
- Prevalence of Self-Care
- Burden on Public Health System
- Long-Term Outlook
Chapter 13 Company Profiles
- Accurna Inc.
- Amgen Inc.
- Arcturus Therapeutics Inc.
- Argos Therapeutics Inc.
- Arrowhead Pharmaceuticals
- Athersys
- Biocad
- Biontech
- Boehringer Ingelheim
- Cansinobio
- Cartesian Therapeutics Inc.
- Chimeron Bio
- Crispr Therapeutics Inc.
- Curevac
- Daiichi Sankyo
- Eli Lilly And Co.
- Elixirgen Therapeutics Inc.
- Etherna Immunotherapies
- Ethris Gmbh
- Genentech (Subsidiary Of Roche)
- Glaxosmithkline Plc
- Greenlight Biosciences Inc.
- HDT Bio Corp.
- In-Cell-Art
- Intellia Therapeutics
- Ionis Pharmaceuticals Inc.
- Johnson & Johnson
- Kernal Biologics Inc.
- Maxcyte Inc.
- Merck Kgaa
- Mercurna
- Moderna Therapeutics
- Novartis
- Nutcracker Therapeutics
- Pfizer
- Phion Therapeutics
- Poseida Therapeutics Inc.
- Quark Pharmaceuticals
- Recode Therapeutics
- Regulus Therapeutics
- Rnaimmune Inc.
- Roche
- Sangamo Therapeutics Inc.
- Sanofi
- Sarepta Therapeutics
- Shanghai Bendao Gene Technology Co., Ltd.
- Stemirna Therapeutics Ltd.
- Strand Therapeutics
- Tiba Biotechnology Llc
- Translate Bio
- Vertex Pharmaceutical
Chapter 14 Appendix A: List of Acronyms
Chapter 15 Appendix B: Professional Organizations
- American Heart Association (AHA)
- The Bill and Melinda Gates Foundation (BMGF)
- Canada's International Development Research Centre (IDRC)
- Center for Devices and Radiological Health (CDRH)
- Center for Drug Evaluation and Research (CDER)
- Centers for Medicare and Medicaid Services (CMS)
- The Coalition for Epidemic Preparedness Innovations (CEPI)
- Hormone Foundation
- International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
- National Center for Biotechnology Information (NCBI)
- National Institute of Aging (NIA)
- Network for Excellence in Health Innovation (NEHI)
- Pharmaceuticals and Medical Devices Agency (PMDA)
- U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)
- U.S. Food and Drug Administration (FDA)
- U.S. National Institutes of Health (NIH)
- World Cancer Research Fund International
- World Health Organization (WHO)
List of Tables
Summary Table: Global Market for mRNA Therapeutics, by Country/Region, Through 2026
Table 1: Global Prevalence of Breast Cancer Cases, by Country/Region, Through 2025
Table 2: Global Epidemiology of Colorectal Cancer, by Region, Through 2030
Table 3: Global Cancer-Related Deaths, by Cancer Type, Through 2030
Table 4: Share of Global Cancer-Related Deaths, by Cancer Type, 2015
Table 5: Case Fatality Rate, Global Viral Outbreaks, 2020
Table 6: Global Incidence Share of Hypertension, by Patient Group Type, 2020
Table 7: Global Prevalence of Angina Pectoris and Stroke (Survivors), Through 2030
Table 8: Global Prevalence of Congestive Heart Failure and Stroke, Through 2030
Table 9: Structural Heart Disease Management Through Medication
Table 10: BMI Categories Based on Increasing Health Risks
Table 11: Trends in Obesity Composition of the Global Population, Through 2025
Table 12: Obesity and Severe Obesity vs. General Population in the U.S., Through 2025
Table 13: Global Share of Diabetes, by Type
Table 14: Global Prevalence of Diabetes, by Type, Through 2040
Table 15: Global Symptomatic Prevalence of Key Musculoskeletal Disorders, Through 2025
Table 16: Global Deaths, by Musculoskeletal Disorder, Through 2030
Table 17: Global Deaths from Digestive Diseases, by Region, Through 2025
Table 18: Global Mortality Share, by Chronic Disease Type, 2019
Table 19: Global Shares of DALYs, by Chronic Disease Type, 2019
Table 20: Estimated World Population and Annual Growth, by Age Group, Through 2030
Table 21: Total Global Population, by Select Country/Region, Through 2030
Table 22: U.S. Population Estimates and Projections, by Age Group, Through 2030
Table 23: Estimates of Anticipated U.S. Life Expectancy at Birth, by Gender, Through 2020
Table 24: European Population Estimates and Projections, by Age Group, Through 2030
Table 25: Japanese Population Estimates and Projections, by Age Group, Through 2030
Table 26: Traditional Vaccines vs. mRNA Vaccines
Table 27: Marketed/Commercial mRNA Vaccines, by Company
Table 28: Clinical Development of mRNA Vaccine, BioNTech
Table 29: Clinical Development of mRNA Vaccine, Moderna
Table 30: Clinical Development of mRNA Vaccine, CureVac
Table 31: Clinical Development of mRNA Vaccine, Translate Bio
Table 32: Clinical Development of mRNA Vaccine, Arcturus Therapeutics
Table 33: Clinical Development of mRNA Vaccine, eTheRNA
Table 34: mRNA Vaccine Development Pipeline, by Others
Table 35: Clinical Development of mRNA Vaccines, by Research Institution
Table 36: mRNA Drugs for Protein Therapy, Metabolic and Rare Diseases, by Company
Table 37: mRNA Therapeutics, Non-viral Delivery for mRNA-Based Protein Therapy and Gene Editing, by Company
Table 38: Clinical Development of mRNA Therapeutics, Moderna
Table 39: Clinical Development of mRNA Therapeutics, Translate Bio
Table 40: Clinical Development of mRNA Therapeutics, BioNTech
Table 41: Clinical Development of mRNA Therapeutics, CureVac
Table 42: Clinical Development of mRNA Therapeutics, Arcturus Therapeutics
Table 43: Clinical Development of mRNA Therapeutics, Argos Therapeutics
Table 44: Clinical Development of mRNA Therapeutics, Mercurna
Table 45: Clinical Development of mRNA Therapeutics, Kernal Biologics
Table 46: Clinical Development of mRNA Therapeutics, Shanghai Bendao Gene Technology
Table 47: Global Market for mRNA Therapeutics, by Country/Region, Through 2026
Table 48: Global Market for mRNA Therapeutics, by Product Segment, Through 2026
Table 49: Global Market Shares of COVID-19 Vaccines, by Type, 2021
Table 50: Global Market Shares of mRNA Vaccines vs. Traditional Vaccines, 2021
Table 51: Global Market Shares of mRNA Therapeutics, by Therapeutic Treatment Type, 2026
Table 52: Global Market for mRNA Therapeutics, by Disease Type, Through 2026
Table 53: SWOT Analysis of the Market for mRNA Therapeutics
Table 54: Global Market for mRNA Therapeutics, by Company, 2021
Table 55: Intellectual Property Landscape for mRNA Therapeutics, by Company, 2021
Table 56: Key Strategic M&A and In-Licensing Deals in the Market for mRNA Therapeutics, by Company, 2019 and 2020
Table 57: Key Strategic Partnerships in the Market for mRNA Therapeutics, by Company, 2019-2020
Table 58: Key Strategic Venture Financing Deals, mRNA Therapeutics, by Company, 2020
Table 59: Countries that Authorized Moderna’s Vaccine for COVID-19
Table 60: Standard Vaccine Pricing Process in the U.S.
Table 61: COVID-19 Vaccine Price Range in the U.S., by Federal Government Purchase
Table 62: Trends in Per Capita Real Gross Domestic Product Growth, by Region, 2016-2019
Table 63: List of Acronyms Used in the Market for mRNA Therapeutics
List of Figures
Summary Figure: Global Market for mRNA Therapeutics, by Country/Region, 2020-2026
Figure 1: Global Prevalence of Breast Cancer Cases, by Region/Country, 2015-2025
Figure 2: Global Epidemiology of Colorectal Cancer, by Region, 2000-2030
Figure 3: Global Cancer Related Deaths, by Cancer Type, 2000-2030
Figure 4: Share of Global Cancer-Related Deaths, by Cancer Type, 2015
Figure 5: Case Fatality Rate Share, Global Viral Outbreaks, 2020
Figure 6: Global Incidence Share of Hypertension, by Patient Group Type, 2020
Figure 7: Global Prevalence of Angina Pectoris and Stroke (Survivors), 2004-2030
Figure 8: Global Prevalence of Congestive Heart Failure and Stroke, 2004-2030
Figure 9: Trends in Obesity Composition of the Global Population, 2012-2025
Figure 10: Obesity and Severe Obesity vs. General Population in the U.S., 2018 and 2025
Figure 11: Global Share of Diabetes, by Type
Figure 12: Global Prevalence of Diabetes, by Type, 2018 and 2040
Figure 13: Global Symptomatic Prevalence of Key Musculoskeletal Disorders, 2012-2025
Figure 14: Global Deaths, by Musculoskeletal Disorder, 2000-2030
Figure 15: Global Deaths from Digestive Diseases, by Region, 2015-2025
Figure 16: Global Mortality Share, by Chronic Disease Type, 2019
Figure 17: Global Shares of DALYs, by Chronic Disease Type, 2019
Figure 18: Estimated World Population and Annual Growth, by Age Group, 2000-2030
Figure 19: Total Global Population, by Select Country/Region, 2000-2030
Figure 20: U.S. Population Estimates and Projections, by Age Group, 2000-2030
Figure 21: Estimates of Anticipated U.S. Life Expectancy at Birth, by Gender, 2005-2020
Figure 22: European Population Estimates and Projections, by Age Group, 2000-2030
Figure 23: Japanese Population Estimates and Projections, by Age Group, 2000-2030
Figure 24: Global Market for mRNA Therapeutics, by Country/Region, 2020-2026
Figure 25: Global Market for mRNA Therapeutics, by Product Segment, 2020-2026
Figure 26: Global Market Shares of mRNA Drugs and Therapies, by Product Type, 2026
Figure 27: Global Market for mRNA Therapeutics, by Disease Type, 2020-2026
Figure 28: Global Market Shares of mRNA Therapeutics, by Leading Company, 2021
Figure 29: Trends in Per Capita Real Gross Domestic Product Growth, by Region, 2016-2019
Samples
LOADING...
Executive Summary
mRNA therapeutics have emerged as a rapidly growing field with multibillion-dollar business potential within the biotherapeutics market. The therapeutic use of mRNA is unique and powerful since it plays a very critical role in human biology and instruct cells to make proteins to circulate throughout the body.
Recent commercial success has shown its potential to transform the biopharma industry, the same way that the first-generation biotech companies (such as Amgen, Biogen and Genentech) did in the 1980s when they began developing recombinant protein therapies called biologics. The COVID-19 pandemic became the first pandemic of the current generation. It created lots of mRNA buzz in the market in terms of appreciating the bigger picture of the mRNA segment and its wider potential of developing precise and individualized therapies targeting diseases beyond viral infections.
Revenue from 2021 is an estimate based on sales of the first two quarters (Q1 & Q2) along with projections of dose orders for 2021 by leading companies. mRNA therapeutics typically include vaccines, drugs and therapies developed through mRNA technology. This market growth is fueled by the increasing incidence of infectious diseases (e.g., COVID-19, Zika, influenza, Ebola, etc.); increasing prevalence of chronic diseases (e.g., cancer, heart diseases, respiratory, CKD, etc.), rare diseases (e.g., methylmalonic acidemia, propionic acidemia, phenylketonuria, glycogen disease, etc.), and metabolic and immune disorders; commercialization of mRNA vaccines; development of personalized therapeutics for cancer; strong pipeline of therapeutics addressing the unmet need for rare diseases; and growing global acceptance for mRNA therapeutics (e.g., COVID-19, Ebola, influenza, HIV) over traditional drugs and vaccines.
The market for 2020 is relatively lower since BioNTech and Moderna received emergency approvals for their vaccines in December 2020. Additionally, 2021 revenue is also an estimate based on sales of first two quarters (Q1 and Q2) along with projections of doses ordered to be delivered by 2021, by leading companies. The U.S. is expected to maintain dominance in the mRNA therapeutics market. This growth is due to the growing geriatric population, rise of COVID-19 pandemic, increasing incidence of infectious diseases, increasing prevalence of chronic diseases, growing demand for transformative therapeutics, increasing acceptance of mRNA vaccines, preventive care, continuous technological advancements, increasing investment, incentives for new product development, unmet need for rare disease treatment, favorable regulatory environment, acceptance of personalized medicine and increasing adoption of treatment adherence technologies and software applications.
Companies Mentioned
- Accurna Inc.
- Amgen Inc.
- Arcturus Therapeutics Inc.
- Argos Therapeutics Inc.
- Arrowhead Pharmaceuticals
- Athersys
- Biocad
- Biontech
- Boehringer Ingelheim
- Cansinobio
- Cartesian Therapeutics Inc.
- Chimeron Bio
- Crispr Therapeutics Inc.
- Curevac
- Daiichi Sankyo
- Eli Lilly And Co.
- Elixirgen Therapeutics Inc.
- Etherna Immunotherapies
- Ethris Gmbh
- Genentech (Subsidiary Of Roche)
- Glaxosmithkline Plc
- Greenlight Biosciences Inc.
- HDT Bio Corp.
- In-Cell-Art
- Intellia Therapeutics
- Ionis Pharmaceuticals Inc.
- Johnson & Johnson
- Kernal Biologics Inc.
- Maxcyte Inc.
- Merck Kgaa
- Mercurna
- Moderna Therapeutics
- Novartis
- Nutcracker Therapeutics
- Pfizer
- Phion Therapeutics
- Poseida Therapeutics Inc.
- Quark Pharmaceuticals
- Recode Therapeutics
- Regulus Therapeutics
- Rnaimmune Inc.
- Roche
- Sangamo Therapeutics Inc.
- Sanofi
- Sarepta Therapeutics
- Shanghai Bendao Gene Technology Co., Ltd.
- Stemirna Therapeutics Ltd.
- Strand Therapeutics
- Tiba Biotechnology Llc
- Translate Bio
- Vertex Pharmaceutical
